{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:23:38Z","timestamp":1789629818158,"version":"build-2803163510"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Reports regarding the relationship between tacrolimus exposure and the risk of acute kidney allograft rejection are conflicting. This may be explained by the previous use of methodological approaches that disregarded important factors in the analysis of longitudinal measurements and time-to-event data. Therefore, in this study, joint models were used to investigate the relationship between repeated measurements of tacrolimus predose concentrations (C\n                      <jats:sub>0<\/jats:sub>\n                      ) and time to acute biopsy-proven acute rejection (BPAR).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This was a post hoc analysis of a randomized controlled trial in which living-donor kidney transplant recipients (KTR) received either a standard, bodyweight-based or\n                      <jats:italic toggle=\"yes\">CYP3A5<\/jats:italic>\n                      genotype-based tacrolimus starting dose. Joint modeling was performed by coupling a mixed-effects model for tacrolimus C\n                      <jats:sub>0<\/jats:sub>\n                      with a Cox proportional hazards model for the risk of rejection. Only the first episode of rejection was considered.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 229 KTRs were included, of whom the incidence of BPAR was 10.5% (n = 24 KTRs) in the first 3 months posttransplant. A total of 3069 tacrolimus measurements were available for the analysis. A joint model adjusted for recipient age and peak panel reactive antibodies demonstrated that tacrolimus C\n                      <jats:sub>0<\/jats:sub>\n                      was associated with risk of rejection. A 1-unit increase in the time-normalized area under the curve for logarithmically (log)-transformed C\n                      <jats:sub>0<\/jats:sub>\n                      represented a change of \u22122.65 in the log of the relative hazard (95% credible interval: \u22125.05 to \u22120.36,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.022).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      A negative association between the cumulative effect of tacrolimus C\n                      <jats:sub>0<\/jats:sub>\n                      and BPAR was observed using joint modeling. This demonstrated that KTRs with lower tacrolimus exposure were at a higher risk of rejection.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001359","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T13:00:13Z","timestamp":1753448413000},"page":"e82-e89","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Tacrolimus Exposure is Associated with Acute Rejection in the Early Phase After Kidney Transplantation: A Joint Modeling Approach"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8759-9866","authenticated-orcid":false,"given":"Maaike R.","family":"Schagen","sequence":"first","affiliation":[{"name":"Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands;"},{"name":"Rotterdam Clinical Pharmacometrics Group, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Assis de Souza","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Boer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse H.","family":"Krijthe","sequence":"additional","affiliation":[{"name":"Pattern Recognition & Bioinformatics Group, Delft University of Technology, Delft, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachida","family":"Bouamar","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Stubbs","sequence":"additional","affiliation":[{"name":"Department of Pathology and Clinical Bioinformatics, Erasmus MC Stubbs Group, University Medical Center Rotterdam, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Hesselink","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda C.M.","family":"de Winter","sequence":"additional","affiliation":[{"name":"Rotterdam Clinical Pharmacometrics Group, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"R1-20251107","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/FTD.0000000000001034","article-title":"TDM is alive and kicking","volume":"45","author":"Lemaitre","year":"2023","journal-title":"Ther Drug Monit."},{"key":"R2-20251107","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R3-20251107","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-199610150-00009","article-title":"Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation","volume":"62","author":"Kershner","year":"1996","journal-title":"Transplantation"},{"key":"R4-20251107","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/00007890-199610150-00005","article-title":"An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group","volume":"62","author":"Laskow","year":"1996","journal-title":"Transplantation"},{"key":"R5-20251107","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/tri.12155","article-title":"Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics","volume":"26","author":"Israni","year":"2013","journal-title":"Transpl Int."},{"key":"R6-20251107","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/tri.12699","article-title":"Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation","volume":"29","author":"Gaynor","year":"2016","journal-title":"Transpl Int."},{"key":"R7-20251107","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/ajt.14109","article-title":"Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: a randomized study","volume":"17","author":"Gatault","year":"2017","journal-title":"Am J Transpl."},{"key":"R8-20251107","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/FTD.0b013e3181a8f02a","article-title":"Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection","volume":"31","author":"Borobia","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R9-20251107","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1399-0012.2009.01021.x","article-title":"Higher tacrolimus trough levels on days 2\u20135 post-renal transplant are associated with reduced rates of acute rejection","volume":"23","author":"O'Seaghdha","year":"2009","journal-title":"Clin Transpl."},{"key":"R10-20251107","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/ajt.12191","article-title":"Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(\u2020)","volume":"13","author":"Bouamar","year":"2013","journal-title":"Am J Transpl."},{"key":"R11-20251107","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","article-title":"The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients","volume":"14","author":"Haufroid","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R12-20251107","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/FTD.0b013e31819c3d6d","article-title":"Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients","volume":"31","author":"Press","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R13-20251107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation","volume":"53","author":"Hesselink","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"R14-20251107","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1097\/TP.0b013e318187c4d1","article-title":"Haplotypic structure of ABCB1\/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients","volume":"86","author":"Bandur","year":"2008","journal-title":"Transplantation"},{"key":"R15-20251107","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.clpt.6100216","article-title":"CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients","volume":"82","author":"Kuypers","year":"2007","journal-title":"Clin Pharmacol Ther."},{"key":"R16-20251107","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharmacol Ther."},{"key":"R17-20251107","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","article-title":"Importance of hematocrit for a tacrolimus target concentration strategy","volume":"70","author":"St\u00f8rset","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"R18-20251107","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00002018-200225100-00003","article-title":"Drug interactions with tacrolimus","volume":"25","author":"van Gelder","year":"2002","journal-title":"Drug Saf."},{"key":"R19-20251107","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.0306-5251.2003.01882.x","article-title":"Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids","volume":"56","author":"Hesselink","year":"2003","journal-title":"Br J Clin Pharmacol."},{"key":"R20-20251107","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ki.2013.484","article-title":"Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation","volume":"85","author":"van Gelder","year":"2014","journal-title":"Kidney Int."},{"key":"R21-20251107","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1093\/ndt\/gfq096","article-title":"High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation","volume":"25","author":"Borra","year":"2010","journal-title":"Nephrol Dial Transpl."},{"key":"R22-20251107","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/FTD.0b013e3182731809","article-title":"Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation","volume":"34","author":"Ro","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R23-20251107","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/ki.2013.465","article-title":"Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure","volume":"85","author":"Sapir-Pichhadze","year":"2014","journal-title":"Kidney Int."},{"key":"R24-20251107","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/tri.12798","article-title":"A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation","volume":"29","author":"Shuker","year":"2016","journal-title":"Transpl Int."},{"key":"R25-20251107","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/TP.0000000000001040","article-title":"Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development","volume":"100","author":"Rodrigo","year":"2016","journal-title":"Transplantation"},{"key":"R26-20251107","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/ajt.14723","article-title":"Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients","volume":"18","author":"Ensor","year":"2018","journal-title":"Am J Transpl."},{"key":"R27-20251107","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.3389\/fimmu.2019.02912","article-title":"Increasing time in therapeutic range of tacrolimus in the first year predicts better outcomes in living-donor kidney transplantation","volume":"10","author":"Song","year":"2019","journal-title":"Front Immunol."},{"key":"R28-20251107","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/TP.0000000000002913","article-title":"Tacrolimus intrapatient variability, time in therapeutic range, and risk of de novo donor-specific antibodies","volume":"104","author":"Davis","year":"2020","journal-title":"Transplantation"},{"key":"R29-20251107","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/TP.0000000000000378","article-title":"Repeated measurements of NT-pro-B-type natriuretic peptide, troponin T or C-reactive protein do not predict future allograft rejection in heart transplant recipients","volume":"99","author":"Battes","year":"2015","journal-title":"Transplantation"},{"key":"R31-20251107","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jclinepi.2022.03.009","article-title":"Joint modeling of endpoints can be used to answer various research questions in randomized clinical trials","volume":"147","author":"van Eijk","year":"2022","journal-title":"J Clin Epidemiol."},{"key":"R32-20251107","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/cpt.2915","article-title":"Tacrolimus and mycophenolic acid exposure are associated with biopsy-proven acute rejection: a study to provide evidence for longer-term target ranges","volume":"114","author":"Meziyerh","year":"2023","journal-title":"Clin Pharmacol Ther."},{"key":"R33-20251107","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/ajt.13691","article-title":"A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation","volume":"16","author":"Shuker","year":"2016","journal-title":"Am J Transpl."},{"key":"R35-20251107","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions","volume":"14","author":"Haas","year":"2014","journal-title":"Am J Transpl."},{"key":"R36-20251107","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jclinepi.2011.11.012","article-title":"Multiple imputation of missing repeated outcome measurements did not add to linear mixed-effects models","volume":"65","author":"Peters","year":"2012","journal-title":"J Clin Epidemiol."},{"key":"R37-20251107","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med."},{"key":"R38-20251107","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/TP.0b013e318186f98a","article-title":"Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial","volume":"86","author":"van Gelder","year":"2008","journal-title":"Transplantation"},{"key":"R39-20251107","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1600-6143.2009.02668.x","article-title":"Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial","volume":"9","author":"Gaston","year":"2009","journal-title":"Am J Transpl."},{"key":"R41-20251107","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1111\/ajt.12955","article-title":"Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial","volume":"14","author":"Budde","year":"2014","journal-title":"Am J Transpl."},{"key":"R42-20251107","first-page":"721","article-title":"Optimization of initial tacrolimus dose using pharmacogenetic testing","volume":"87","author":"Thervet","year":"2010","journal-title":"Clin Pharmacol Ther."},{"key":"R43-20251107","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3390\/jcm11051392","article-title":"Risk factors of rejection in renal transplant recipients: a narrative review","volume":"11","author":"Oweira","year":"2022","journal-title":"J Clin Med."},{"key":"R44-20251107","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/17425255.2023.2250251","article-title":"Individualized dosing algorithms for tacrolimus in kidney transplant recipients: current status and unmet needs","volume":"19","author":"Schagen","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R45-20251107","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/bcp.16121","article-title":"Removing the physician from the equation: patient-controlled, home-based therapeutic drug self-monitoring of tacrolimus","volume":"91","author":"Hazenbroek","year":"2025","journal-title":"Br J Clin Pharmacol."},{"key":"R46-20251107","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/dom.15575","article-title":"An update review of post-transplant diabetes mellitus: concept, risk factors, clinical implications and management","volume":"26","author":"Kanbay","year":"2024","journal-title":"Diabetes Obes Metab."},{"key":"R47-20251107","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 kidney meeting report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transpl."},{"key":"R48-20251107","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bcp.13838","article-title":"A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients","volume":"85","author":"Andrews","year":"2019","journal-title":"Br J Clin Pharmacol."},{"key":"R49-20251107","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1111\/bcp.16098","article-title":"Therapeutic drug monitoring of tacrolimus after kidney transplantation: trough concentration or area under curve-based monitoring?","volume":"91","author":"van Gelder","year":"2025","journal-title":"Br J Clin Pharmacol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:00:50Z","timestamp":1762542050000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001359","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"2025-01-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}